Low Price Pharma Stocks List – Pharma Penny Stocks India

The table below shows the Low Price Pharma Stocks List – Pharma Penny Stocks India based on the Highest Market Capitalization.

Best Low Price Pharma Stocks

The table below shows the Best Low Price Pharma Stocks based on 1 Year Return.

Low Price Pharma Stocks Nse

The table below shows Low Price Pharma Stocks Nse based on 1 Month Return.

Low Price Pharma Stocks

The table below shows Pharma Penny Stocks based on the Highest Daily Volume.

Low Price Pharma Stocks India

The table below shows Pharma Penny Stocks India based on the PE Ratio.

Low Price Pharma Stocks Under 10 Rs

The table below shows Pharma Penny Stocks Under 10 Rs.

Low Price Pharma Stocks List – FAQs

1. Which are the Best Pharma Stocks?

• Best Pharma Stocks #1: Piramal Pharma Ltd
• Best Pharma Stocks #2: Marksans Pharma Ltd
• Best Pharma Stocks #3: Sun Pharma Advanced Research Co Ltd
• Best Pharma Stocks #4: SeQuent Scientific Ltd
• Best Pharma Stocks #5: Suven Life Sciences Ltd

The stocks mentioned are ranked according to their one-year performance.

2. Is it good to invest in Pharma Penny Stocks?

Investing in pharmaceutical penny stocks carries a high risk due to volatility, limited liquidity, and uncertainty. It’s crucial to research thoroughly, consider your risk tolerance, and diversify your portfolio wisely.

3. What are the Low Price NSE Pharma Stocks?

Pharmaceutical stocks encompass companies researching, developing, manufacturing, and distributing drugs and healthcare products. A stock price below 50 Rs may be considered “low-priced” in this sector, but it’s essential to evaluate such stocks based on various factors before investing.

4. What is the future of Pharma Penny Stocks?

The future of Pharma Penny Stocks is uncertain and highly speculative, influenced by regulatory changes, drug developments, and market sentiment. Potential investors should exercise caution and conduct thorough research before investing.

Introduction to Low Price Pharma Stocks List

Low Price Pharma Stocks List – Highest Market Capitalization

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is ₹30,105.61 crore. The stock’s 1-month return is 17.01%, while its 1-year return is 70.85%. It is currently 35.04% away from its 52-week high.

Piramal Pharma Ltd is a leading pharmaceutical company engaged in contract development and manufacturing, complex generics, and consumer healthcare. The company has a strong global presence and provides high-quality pharmaceutical products and services. With a focus on innovation and R&D, Piramal Pharma continues to expand its offerings in speciality pharmaceuticals and healthcare solutions.

The company’s diverse portfolio includes APIs, drug formulations, and consumer healthcare products. With an emphasis on sustainable growth and strategic acquisitions, Piramal Pharma is continuously strengthening its market position. The company’s commitment to quality and regulatory compliance makes it a trusted partner in the global pharmaceutical industry.

Marksans Pharma Ltd

The Market Cap of Marksans Pharma Ltd is ₹10,206.15 crore. The stock’s 1-month return is 6.93%, while its 1-year return is 39.89%. It is currently 59.27% away from its 52-week high.

Marksans Pharma Ltd is a globally recognised pharmaceutical company specialising in the development, manufacturing, and marketing of generic pharmaceutical formulations. The company operates across multiple international markets, with a strong presence in regulated markets such as the US, UK, and Australia. Its product portfolio spans multiple therapeutic segments, including pain management, cardiovascular health, and gastrointestinal treatments.

Marksans Pharma focuses on innovation and strategic expansion to maintain its competitive edge. By leveraging advanced manufacturing capabilities and robust R&D investments, the company continues to develop cost-effective and high-quality pharmaceutical products. It aims to strengthen its position in the global pharmaceutical market through continued product launches and geographical expansion.

Sun Pharma Advanced Research Co Ltd

The Market Cap of Sun Pharma Advanced Research Co Ltd is ₹4,725.03 crore. The stock’s 1-month return is 30.48%, while its 1-year return is -62.11%. It is currently 224.73% away from its 52-week high.

Sun Pharma Advanced Research Company (SPARC) is a research-driven pharmaceutical entity focused on novel drug discovery and development. As an innovation arm of Sun Pharmaceutical Industries, SPARC is dedicated to developing cutting-edge pharmaceutical solutions, including new chemical entities (NCEs) and novel drug delivery systems (NDDS). The company’s R&D efforts primarily target oncology, neurology, ophthalmology, and dermatology.

Despite facing challenges in recent financial performance, SPARC continues to invest heavily in drug development and strategic partnerships. The company aims to deliver breakthrough therapies that address unmet medical needs and improve patient outcomes. With an emphasis on regulatory approvals and clinical advancements, SPARC remains committed to innovation in the global pharmaceutical industry.

Best Low Price Pharma Stocks – 1 Year Return

Sudarshan Pharma Industries Ltd
The Market Cap of Sudarshan Pharma Industries Ltd is ₹763.85 crore. The stock’s 1-month return is 8.5%, while its 1-year return is 303.41%. It is currently 68.56% away from its 52-week high.

Sudarshan Pharma Industries Ltd provides specialty chemicals, pharma intermediates, and formulations to global customers. It caters to multiple sectors, including pharma, cosmetics, and nutraceuticals.

The company is focused on contract manufacturing and custom synthesis, leveraging partnerships to deliver tailored chemical solutions. It continues to build scale and expand its international reach.

Shukra Pharmaceuticals Ltd
The Market Cap of Shukra Pharmaceuticals Ltd is ₹919.55 crore. The stock’s 1-month return is -90.74%, while its 1-year return is 167.82%. It is currently 29.29% away from its 52-week high.

Shukra Pharmaceuticals Ltd manufactures a range of pharmaceutical formulations, including tablets, capsules, and injectables. It provides contract manufacturing services for several domestic companies.

With a focus on operational scalability, it aims to expand its manufacturing and customer base. Its product lines support chronic and acute therapies, contributing to long-term growth.

Jagsonpal Pharmaceuticals Ltd
The Market Cap of Jagsonpal Pharmaceuticals Ltd is ₹1,512.83 crore. The stock’s 1-month return is 4.47%, while its 1-year return is 89.46%. It is currently 43.98% away from its 52-week high.

Jagsonpal Pharmaceuticals Ltd is engaged in the development and marketing of a range of pharmaceutical products in India. The company has a strong presence in therapeutic areas like women’s health and orthopedics.

With a legacy of consistent product delivery, it has built strong relationships with healthcare professionals. The company continues to focus on strengthening its domestic portfolio and exploring growth opportunities.

Low Price Pharma Stocks Nse – 1 Month Return

Wanbury Ltd
The Market Cap of Wanbury Ltd is ₹831.06 crore. The stock’s 1-month return is 55.57%, while its 1-year return is 58.55%. It is currently 27.57% away from its 52-week high.

Wanbury Ltd focuses on the formulation and export of pharmaceutical products. It is known for its strength in pain management, anti-diabetic, and anti-inflammatory drugs across several countries.

The company has a strong emphasis on compliance, innovation, and operational excellence. Its manufacturing facilities are USFDA and EU-approved, enabling penetration into high-growth global markets.

Fermenta Biotech Ltd
The Market Cap of Fermenta Biotech Ltd is ₹851.46 crore. The stock’s 1-month return is 24.59%, while its 1-year return is 79.17%. It is currently 53.74% away from its 52-week high.

Fermenta Biotech Ltd is a key manufacturer of Vitamin D3 and enzymes for pharmaceutical and food industries. It operates in both B2B and B2C segments through its global network.

The company’s sustainability initiatives include green chemistry and eco-friendly practices. With diverse applications for its products, it plays a crucial role in the health and nutrition industries worldwide.

Indoco Remedies Ltd
The Market Cap of Indoco Remedies Ltd is ₹2,250.46 crore. The stock’s 1-month return is 22.07%, while its 1-year return is -28.22%. It is currently 58.81% away from its 52-week high.

Indoco Remedies Ltd operates in both domestic formulations and international businesses, offering a range of branded and generic products. It focuses on respiratory, dental, and anti-infective segments.

The company emphasises R&D and regulatory compliance, supplying to multiple global markets. Its vertically integrated operations support the development and manufacture of high-quality pharmaceutical products.

Pharma Penny Stocks – Highest Day Volume

Morepen Laboratories Ltd

The Market Cap of Morepen Laboratories Ltd is ₹2,713.47 crore. The stock’s 1-month return is 5.97%, while its 1-year return is 4.92%. It is currently 103.76% away from its 52-week high.

Morepen Laboratories Ltd is a well-established pharmaceutical company involved in the research, development, and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and diagnostic devices. The company has a strong presence in both domestic and international markets, catering to various segments, including over-the-counter (OTC) drugs and branded generics.

Despite a decline in its one-month return, the company’s stock has maintained relative stability over the past year. Morepen Laboratories Ltd continues to invest in research and development, with a focus on innovation and expansion. The company is also strengthening its diagnostic business and increasing its API production capabilities to sustain long-term growth.

Syncom Formulations (India) Ltd
The Market Cap of Syncom Formulations (India) Ltd is ₹1,607.40 crore. The stock’s 1-month return is 11.54%, while its 1-year return is 39.59%. It is currently 63.16% away from its 52-week high.

Syncom Formulations (India) Ltd is a pharmaceutical company that manufactures and markets high-quality generic drugs. The company specialises in producing finished dosage forms and APIs, catering to various global markets.

Syncom Formulations has a diverse product portfolio that includes medicines in therapeutic areas such as antibiotics, anti-inflammatory drugs, and central nervous system treatments. It focuses on providing affordable and accessible medicines to patients around the world while maintaining high-quality standards.

SeQuent Scientific Ltd
The Market Cap of SeQuent Scientific Ltd is ₹3,426.74 crore. The stock’s 1-month return is -11.01%, while its 1-year return is 11.4%. It is currently 75.53% away from its 52-week high.

SeQuent Scientific Ltd is a leading animal health company that focuses on manufacturing and marketing veterinary pharmaceutical products. Its portfolio includes active pharmaceutical ingredients and finished dosage forms.

With a presence in over 100 countries, the company serves livestock and companion animal segments. It emphasises quality manufacturing, regulatory compliance, and continuous innovation in animal care solutions.

Pharma Penny Stocks India – PE Ratio

Bliss GVS Pharma Ltd
The Market Cap of Bliss GVS Pharma Ltd is ₹1,265.50 crore. The stock’s 1-month return is -4.58%, while its 1-year return is 1.69%. It is currently 54.45% away from its 52-week high.

Bliss GVS Pharma Ltd is a global pharmaceutical company specialising in suppositories, semi-solids, and oral solid dosage forms. It has a wide global footprint and a strong product pipeline.

The company continues to grow its presence in Africa, Asia, and Latin America. With robust research facilities and WHO-GMP compliant plants, it ensures high-quality healthcare delivery.

Anuh Pharma Ltd
The Market Cap of Anuh Pharma Ltd is ₹1,111.73 crore. The stock’s 1-month return is -1.96%, while its 1-year return is -37.27%. It is currently 61.48% away from its 52-week high.

Anuh Pharma Ltd specialises in the production of bulk drugs and active pharmaceutical ingredients for global markets. It serves therapeutic areas such as antibiotics, anti-malarials, and macrolides.

With decades of experience, the company maintains high regulatory standards and exports to over 90 countries. Its emphasis on continuous improvement keeps it competitive in global supply chains.

Alembic Ltd
The Market Cap of Alembic Ltd is ₹2,571.16 crore. The stock’s 1-month return is 8.44%, while its 1-year return is 7.32%. It is currently 68.78% away from its 52-week high.

Alembic Ltd is a part of the Alembic Group, known for its longstanding presence in the Indian pharmaceutical space. It is engaged in the manufacture of bulk drugs and intermediates.

The company is diversified across therapeutic areas and markets its products in both domestic and global markets. It continues to invest in technology and infrastructure to enhance operational efficiency.

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.